Technology ID
E-002-2014

Human Antibodies Against Middle East Respiratory Syndrome Coronavirus

Linked ID
NCI-E-002-2014
Inventors
Dimiter Dimitrov ()
Kwok Yuen ()
Tianlei Ying (NCI)
Tina Ju (NCI)
Lead Inventors
Dimiter Dimitrov ()
Co-Inventors
Kwok Yuen ()
Tianlei Ying (NCI)
Tina Ju (NCI)
Development Status
Discovery (Lead Identification)
Applications
Therapeutics
ICs
NCI
Commercial Applications
  • Antibody-based therapeutics for treatment of MERS-CoV infection
No effective therapeutics or vaccines against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) are available. The human-to-human aspect of transmission and the high mortality rate associated with MERS-CoV infection have raised concerns over the potential for a future MERS-CoV pandemic and emphasized the need for development of effective therapeutics and vaccines.The MERS-CoV-S protein is believed to be required for binding and virus entry during MERS-CoV infection. The antibodies of this technology represent candidate antibody-based therapeutics for treatment of MERS-CoV infection. Researchers at the NCI have developed human antibodies that target MERS-CoV. Certain of these antibodies bind with epitopes of the MERS-CoV receptor binding domain (RBD) of MERS-CoV spike (S) protein with high affinity and are capable of neutralizing the virus as demonstrated in a pseudovirus assay.
Competitive Advantages
  • No vaccine or other biologic therapy is available, and this antibody provides high binding (sub-nanomolar) affinity, and relative safety with long half-lives.

Request More Info

Licensing Contact